Jubilant Pharmova Ltd logo

Jubilant Pharmova Ltd

JUBLPHARMA NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹13,886 Cr
Volatility
Low Risk
P/E Ratio
39.17
EBITDA
₹1,326 Cr
Return on Equity
5.6%
Debt to Equity
0.51
Book Value
₹445.26
EPS
₹14.96
52W High
₹1,184.8
52W Low
₹786.05

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Jubilant Pharmova Ltd insights

44 extracted metrics + investor summaries across FY14–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

2
  • Company has been maintaining a healthy dividend payout of 43.9%
  • Company's working capital requirements have reduced from 28.6 days to 13.4 days

Weaknesses

3
  • The company has delivered a poor sales growth of 6.31% over past five years.
  • Company has a low return on equity of 4.91% over last 3 years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
14.46% ↗
Net Income Growth
-52.47% ↗
Cash Flow Change
14.43% ↗
ROE
-58.24% ↘
ROCE
-44.84% ↘
EBITDA Margin (Avg.)
-5.86% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk high

Jubilant Pharmova Ltd is a mid-cap healthcare company with a market cap of Rs 14,190 Cr trading at a PE of 40.4x. The company shows improving TTM sales growth of 16% but declining profits at -20% TTM, with a 3-year ROE of only 5% and a price-to-book of 2x.

Bull Case 7
  • TTM revenue growth has accelerated to 16%, significantly above the 5-year compounded sales CAGR of 6%, indicating improving business momentum
  • 3-year compounded profit growth of 47% shows the company went through a significant earnings recovery cycle from prior lows
  • Working capital efficiency has improved sharply with requirements reducing from 28.6 days to 13.4 days, freeing up cash for operations
  • Healthy dividend payout ratio of 43.9% demonstrates management's commitment to returning capital to shareholders
  • 3-year stock CAGR of 27% reflects market recognition of the company's turnaround trajectory
  • 10-year stock CAGR of 10% shows the company has delivered reasonable long-term wealth creation for patient investors
  • Price-to-book ratio of 2x is relatively modest for a healthcare company, suggesting the stock is not excessively priced on asset basis
Bear Case 8
  • TTM profit growth is -20%, indicating earnings are declining even as revenues grow, pointing to margin compression or rising costs
  • 5-year compounded profit CAGR of -13% shows a sustained inability to grow bottom-line over a medium-term horizon
  • 3-year ROE of only 5% and last year ROE of 7% are well below cost of equity, indicating poor capital efficiency
  • PE of 40.4x is elevated relative to the weak earnings profile with 10-year profit CAGR of just 1%, suggesting the stock prices in significant future improvement
  • 5-year compounded sales growth of only 6% reflects structurally slow top-line expansion for a pharma business
  • 1-year stock return of -17% indicates recent market skepticism about near-term fundamentals
  • Company might be capitalizing interest costs, which could overstate reported profitability and asset values
  • 10-year compounded profit growth of merely 1% suggests the business has struggled to generate meaningful earnings growth across full cycles

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2d ago
Positives 3
  • ₹22.10 crore tax demand deleted Jul 17

    Rectification order received on July 15, 2026 deleting a tax demand of Rs 22.10 crores for AY 2020-21, removing a potential cash outflow.

  • ₹5 dividend recommended Jul 29

    Board recommends ₹5 per share dividend with record date July 24, 2026. 48th AGM scheduled for August 26, 2026 via VC/OAVM.

  • Strong ESG 'Leader' rating Aug 1

    BRSR for FY26 filed with 'Leader' status from NSE Sustainability, reflecting strong environmental and governance metrics.

Neutral 3
  • Investor meet Aug 13-14 Aug 5

    Jubilant Pharmova will meet institutional investors in Mumbai on August 13-14, 2026 to discuss Q1FY27 earnings ahead of the August 10 results filing.

  • Q1FY26 board meeting rescheduled Aug 5

    Board meeting rescheduled to August 10, 2026 to consider Q1FY26 results. Trading window closed until August 12, 2026.

  • MD re-appointment postal ballot Jul 18

    Shareholder approval sought via postal ballot to re-appoint Priyavrat Bhartia and Arjun Shanker Bhartia as Managing Directors for three years from June 1, 2026.

TL;DR: Jubilant Pharmova is in a steady phase with no material headwinds. The deletion of a ₹22.10 crore tax demand and a proposed ₹5 dividend signal financial stability, while strong ESG ratings enhance institutional appeal. With Q1FY27 results due August 10 and an investor meet following shortly after, near-term catalysts depend on earnings performance.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,587
1,680
1,677
1,759
1,732
1,752
1,822
1,929
1,901
1,966
2,122
2,290
2,229
Expenses
1,419
1,438
1,459
1,487
1,480
1,463
1,535
1,584
1,611
1,625
1,833
1,951
1,981
Operating Profit
168
242
218
271
252
289
287
345
290
341
289
339
248
OPM %
11%
14%
13%
15%
15%
17%
16%
18%
15%
17%
14%
15%
11%
Other Income
9
19
49
-151
410
8
-10
9
12
4
-19
10
20
Interest
62
66
71
73
71
61
56
53
49
50
56
56
54
Depreciation
90
97
95
101
91
91
91
95
98
105
121
117
127
PBT
25
98
101
-54
500
144
130
206
154
190
93
176
86
Tax %
76%
37%
34%
15%
4%
29%
23%
27%
34%
37%
40%
32%
35%
Net Profit
6
62
66
-62
482
102
101
151
102
120
56
119
56
EPS in Rs
0.4
3.92
4.19
-3.68
30.26
6.45
6.33
9.64
6.46
7.55
3.51
7.5
3.55
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
5,751
5,749
5,861
7,518
9,111
5,976
6,099
6,130
6,282
6,703
7,234
8,280
8,608
Expenses
5,141
4,493
4,510
5,995
7,367
4,428
4,695
4,980
5,503
5,802
6,061
7,020
7,390
Operating Profit
610
1,256
1,352
1,522
1,744
1,548
1,403
1,150
779
901
1,173
1,260
1,218
OPM %
11%
22%
23%
20%
19%
26%
23%
19%
12%
13%
16%
15%
14%
Other Income
86
4
19
36
-249
225
263
8
-9
-76
416
7
15
Interest
368
371
341
284
220
200
184
145
188
272
240
212
217
Depreciation
288
347
291
415
371
340
349
382
554
382
369
440
470
PBT
40
542
738
859
904
1,233
1,133
630
28
170
981
614
546
Tax %
200%
29%
22%
26%
36%
27%
26%
34%
333%
57%
15%
35%
—
Net Profit
-40
387
575
634
577
898
836
413
-65
73
836
398
351
EPS in Rs
-3.63
24.6
36.14
40.35
36.06
56.39
52.47
25.98
-3.83
4.84
52.69
25.02
22.11
Div. Payout %
-83%
12%
8%
7%
12%
9%
10%
19%
-130%
102%
9%
20%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
16
16
16
16
16
16
16
16
16
16
Reserves
2,438
2,951
3,420
4,071
4,793
5,588
4,726
5,303
5,383
5,418
6,239
7,077
Borrowings
4,793
4,493
4,045
3,469
4,840
4,808
2,830
3,192
3,677
3,664
2,731
3,615
Other Liabilities
1,372
1,280
1,417
1,902
1,670
1,898
1,192
1,319
1,853
2,240
3,598
4,564
Total Liabilities
8,619
8,740
8,899
9,457
11,319
12,310
8,763
9,830
10,929
11,338
12,584
15,272
Fixed Assets
4,911
5,104
5,107
5,401
5,648
6,340
4,609
4,871
5,183
5,091
5,176
6,966
CWIP
597
611
684
671
901
768
897
1,090
1,562
2,103
3,630
4,040
Investments
40
85
103
124
115
69
241
239
256
42
44
61
Other Assets
3,071
2,939
3,006
3,262
4,654
5,133
3,017
3,631
3,928
4,101
3,735
4,205
Total Assets
8,619
8,740
8,899
9,457
11,319
12,310
8,763
9,830
10,929
11,338
12,584
15,272
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
783
1,099
1,268
1,303
1,122
1,543
1,784
838
661
971
1,072
1,227
Investing
-362
-309
-465
-614
-1,018
-267
-727
-323
-474
-596
512
-1,143
Financing
-503
-843
-686
-901
657
-1,050
-1,709
-33
-157
-432
-1,453
95
Net Cash Flow
-82
-52
117
-212
761
225
-652
482
30
-58
132
179
Free Cash Flow
434
760
806
819
473
975
1,270
241
-135
83
-38
-120
CFO/OP
141
91
104
103
84
116
155
90
111
131
112
114
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
52
60
63
55
51
79
49
55
56
50
45
47
Inventory Days
169
207
223
177
147
463
268
308
268
220
178
170
Days Payable
99
106
137
145
106
273
124
139
160
146
158
170
Cash Conversion Cycle
122
162
149
87
92
268
194
224
165
124
65
47
Working Capital Days
12
4
50
45
45
62
74
56
57
56
16
13
ROCE %
6%
13%
15%
15%
16%
15%
12%
10%
3%
7%
10%
9%

Shareholding Pattern

As of Jun 2026
Promoters 47.68%
Public 17.16%
FIIs 15.87%
DIIs 12.40%
Others 6.89%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
50.68%
47.68%
47.68%
47.68%
47.68%
47.68%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
23.21%
0.00%
19.06%
19.49%
17.94%
16.96%
17.22%
17.40%
16.57%
15.96%
15.90%
15.87%
DIIs
0.78%
1.15%
0.40%
0.43%
0.05%
0.04%
0.39%
1.62%
0.40%
1.63%
1.65%
1.50%
3.78%
4.07%
5.66%
6.98%
7.05%
9.53%
10.52%
11.22%
11.62%
12.40%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
1.24%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
16.07%
16.98%
19.03%
18.97%
19.27%
19.35%
19.01%
18.68%
18.69%
18.25%
18.24%
18.76%
18.71%
17.79%
18.09%
18.09%
17.75%
17.97%
18.02%
17.85%
17.57%
17.16%
Others
32.47%
31.19%
29.89%
29.92%
30.00%
29.93%
29.92%
29.02%
28.98%
29.44%
6.22%
29.06%
7.77%
7.97%
7.63%
7.30%
7.31%
7.42%
7.22%
7.29%
7.23%
6.89%
No. of Shareholders
0
61,942
87,493
1,13,776
1,09,420
1,08,063
1,09,410
1,05,632
97,935
93,375
89,376
86,588
92,264
81,992
89,456
1,02,442
96,526
99,673
93,336
90,133
86,347
82,703

Documents

1
Concall - Aug 2017 Aug 2017
2
Concall - Jun 2018 Jun 2018
3
Concall - Mar 2022 Mar 2022
4
Concall - Nov 2022 Nov 2022
5
Concall - May 2023 May 2023

Frequently Asked Questions about Jubilant Pharmova Ltd

What does Jubilant Pharmova Ltd do?
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]
Where is Jubilant Pharmova Ltd (JUBLPHARMA) listed?
Jubilant Pharmova Ltd is listed on the Indian stock exchanges. It is listed on NSE: JUBLPHARMA and BSE: 530019. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Jubilant Pharmova Ltd belong to?
Jubilant Pharmova Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd has a market capitalisation of approximately ₹13886.13 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Jubilant Pharmova Ltd?
The Price-to-Earnings (PE) ratio of Jubilant Pharmova Ltd is 39.17. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Jubilant Pharmova Ltd?
Over the past 52 weeks, Jubilant Pharmova Ltd has traded between a low of ₹786.05 and a high of ₹1,184.8. This range helps investors understand the stock's price volatility and recent trading levels.
Does Jubilant Pharmova Ltd pay dividends?
Yes, Jubilant Pharmova Ltd has a dividend yield of 0.58%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd has a Return on Equity (ROE) of 5.60%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Jubilant Pharmova Ltd on Tapetide?
On Tapetide, you can view Jubilant Pharmova Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]

Website jubl.com
CEO Mr. Priyavrat Bhartia MBA
Employees 5,547
Listed 2003-06-16
Face Value ₹ 1
Issued Size 15,92,81,139

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List